Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Brodsky: Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-rela.... (0.09 sec) 

[PDF] Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of …


RA Brodsky, P Principles - Annals of Internal Medicine, 2008 - Am Coll Physicians
Y ou are asked to see a 37-year-old male carpenter who was noted to be anemic and mildly
thrombocytopenic during a routine physical examination. The patient has been married for 11
years and has a 5-year-old son and an 8-year-old daughter. He reports that he has been ...
Cited by 13 - Related articles - BL Direct - All 13 versions

[CITATION] GPI-ANCHORED PROTEINS


CMHIN PNH
Related articles

How I treat paroxysmal nocturnal hemoglobinuria

- hematologylibrary.org
RA Brodsky - Blood, 2009 - bloodjournal.hematologylibrary.org
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with
hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of
the disease result from complement-mediated intravascular hemolysis. Allogeneic bone ...
Cited by 3 - Related articles

Eculizumab, a terminal complement inhibitor, improves anaemia in patients with …


J Schubert, P Hillmen, A Roth, N Young, M … - British Journal of …, 2008 - interscience.wiley.com
In paroxysmal nocturnal haemoglobinuria (PNH), chronic destruction of PNH red blood cells
(RBCs) by complement leads to anaemia and other serious morbidities. Eculizumab inhibits
terminal complement-mediated PNH RBC destruction by targeting C5. In the phase III, ...
Cited by 6 - Related articles - All 3 versions

Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria


RA Brodsky - Blood reviews, 2008 - Elsevier
PNH is an uncommon acquired hemolytic anemia that often manifests with hemoglobinuria, abdominal
pain, smooth muscle dystonias, fatigue, and thrombosis. The disease results from the expansion
of hematopoietic stem cells harboring a mutation in a gene, PIG-A, that is required for the ...
Cited by 9 - Related articles - All 12 versions

[CITATION] The investigation of HMGA2 dysregulation and promoter mutations in PIG-M in the …


RJ Kelley, RM Tooze, GM Doody, SJ Richards, P … - Blood, 2008
Cited by 2 - Related articles

Safety and efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria …


RA Brodsky, P Hillmen, J Schubert, L … - ASCO Meeting …, 2007 - meeting.ascopubs.org
Background: Myelodysplastic syndrome (MDS) and aplastic anemia (AA) have been reported
to be associated with the development of the acquired clonal hemolytic and bone marrow failure
disorder, paroxysmal nocturnal hemoglobinuria (PNH). Two recent phase 3 clinical ...
Cited by 2 - Related articles - All 2 versions

Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in …


GL Mukhina, JT Buckley, JP Barber, RJ … - British journal of …, 2001 - ingentaconnect.com
Page 1. 476 q 2001 Blackwell Science Ltd Multilineage glycosylphosphatidylinositol
anchor-deficient haematopoiesis in untreated aplastic anaemia Galina L. Mukhina, 1 J. Thomas
Buckley 2 James P. Barber, 1 Richard J. Jones 1 and Robert A. Brodsky 1 ...
Cited by 49 - Related articles - BL Direct - All 4 versions

On the origin of multiple mutant clones in paroxysmal nocturnal hemoglobinuria

- alphamedpress.org
A Traulsen, JM Pacheco, D Dingli - Stem Cells, 2007 - AlphaMed Press
The pool of hematopoietic stem cells that actively contributes to hematopoiesis is small, and
the cells replicate slowly. Patients with paroxysmal nocturnal hemoglobinuria invariably have
a mutation in the PIG-A gene, and many have more than one clone of PIG-A mutated ...
Cited by 11 - Related articles - BL Direct - All 5 versions

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment …

- hematologylibrary.org
RA Brodsky, NS Young, E Antonioli, AM … - …, 2008 - bloodjournal.hematologylibrary.org
The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated
in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations
with results from an open-label, non–placebo-controlled, 52-week, phase 3 clinical safety ...
Cited by 55 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google